Pharma Focus Asia

A Novel Oral Therapy Discovered to Treat Adult Patients with Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

Blueprint Medicines Corporation discovered GAVRETO™ for the treatment of adult patients with metastatic Rearranged during Transfection (RET) fusion-positive Non-small Cell Lung Cancer (NSCLC).

GAVRETO an oral, RET-targeted therapy is taken daily twice. The oral therapy is designed to selectively and potently inhibit RET alterations which gives rise to many types of cancers, including approximately 1 to 2 percent of patients with NSCLC.

GAVRETO™ oral therapy makes a potential benefit in changing standards of care for patients with RET fusion-positive non-small cell lung cancer, where the treatments for patients are limited.

Some of the major side effects with GAVRETO include interstitial lung disease/pneumonitis, hypertension, hepatotoxicity, hemorrhagic events, risk of impaired wound healing and risk of embryo-fetal toxicity.

U.S. Food and Drug Administration (FDA) has approved GAVRETO™ (pralsetinib) for the treatment of adult patients with metastatic RET fusion-positive Non-small Cell Lung Cancer (NSCLC).

Latest Issue
Get instant
access to our latest e-book
MFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Gibco Adherent Kidney Media PanelCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024ISPE Singapore Affiliate Conference & Exhibition 2024Rehab Expo 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024